NASDAQ:INGN - Inogen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$90.12 -4.56 (-4.82 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$90.12
Today's Range$89.7901 - $94.57
52-Week Range$89.79 - $287.79
Volume431,332 shs
Average Volume732,407 shs
Market Capitalization$1.97 billion
P/E Ratio39.18
Dividend YieldN/A
Beta1.51
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

Receive INGN News and Ratings via Email

Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INGN
CUSIPN/A
Phone805-562-0500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$358.11 million
Cash Flow$2.8145 per share
Book Value$14.54 per share

Profitability

Net Income$51.85 million

Miscellaneous

Employees1,099
Market Cap$1.97 billion
Next Earnings Date4/29/2019 (Estimated)
OptionableOptionable

Inogen (NASDAQ:INGN) Frequently Asked Questions

What is Inogen's stock symbol?

Inogen trades on the NASDAQ under the ticker symbol "INGN."

How were Inogen's earnings last quarter?

Inogen Inc (NASDAQ:INGN) posted its quarterly earnings data on Tuesday, February, 26th. The medical technology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.25 by $0.19. The medical technology company earned $86.50 million during the quarter, compared to the consensus estimate of $82.06 million. Inogen had a return on equity of 18.60% and a net margin of 14.48%. The firm's quarterly revenue was up 35.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.03) earnings per share. View Inogen's Earnings History.

When is Inogen's next earnings date?

Inogen is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for Inogen.

What guidance has Inogen issued on next quarter's earnings?

Inogen issued an update on its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $430-440 million, compared to the consensus revenue estimate of $436.35 million.

What price target have analysts set for INGN?

6 equities research analysts have issued 1-year target prices for Inogen's shares. Their predictions range from $170.00 to $258.00. On average, they expect Inogen's share price to reach $195.80 in the next year. This suggests a possible upside of 117.3% from the stock's current price. View Analyst Price Targets for Inogen.

What is the consensus analysts' recommendation for Inogen?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inogen.

What are Wall Street analysts saying about Inogen stock?

Here are some recent quotes from research analysts about Inogen stock:
  • 1. Needham & Company LLC analysts commented, "INGN beat consensus revenue and EPS in 4Q18 and management maintained its 2019 guidance for revenue and adjusted EBITDA. The revenue upside was driven by the DTC sales force expansion and was partially offset by slower domestic B2B sales as a single large customer slowed its orders. Gross margin was up Y/Y and beat our estimate while operating margin was down Y/Y and beat our estimate. INGN continues to see the benefit of its DTC sales force expansion as DTC sales grew 50% in 4Q18. We expect the ongoing sales force expansion, new product cycle, and the market shift to POCs to sustain strong growth and drive upside to consensus and we reiterate our Strong Buy rating." (2/27/2019)
  • 2. According to Zacks Investment Research, "Inogen outperformed the industry in a year’s time. The company continues to gain from its strong portfolio of portable oxygen concentrators (POC) which has been lending it a competitive edge in the MedTech space. Solid business-to-business revenues also buoy optimism. These apart, the company’s direct-to-consumer unit performed exceedingly well in recent times. Moreover, management remains optimistic about its international revenues, which saw solid growth in Europe in recent times. The raised revenue guidance for 2018 is also an added positive. Inogen issued a bullish guidance for 2019 as well. On the flip side, Inogen’s rental revenues declined on a year-over-year basis in recent times. In fact, the company expects rental revenues to remain down in 2018 and grow modestly in 2019. Rising operating expenses are discouraging as well. In the LTOT market, POC adoption continues to face significant headwinds." (2/14/2019)

Has Inogen been receiving favorable news coverage?

Media headlines about INGN stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Inogen earned a coverage optimism score of 0.6 on InfoTrie's scale. They also assigned media coverage about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.

Who are some of Inogen's key competitors?

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include NVIDIA (NVDA), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alibaba Group (BABA), Netflix (NFLX), Medivation (MDVN), Micron Technology (MU), ABIOMED (ABMD) and Adobe (ADBE).

Who are Inogen's key executives?

Inogen's management team includes the folowing people:
  • Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)
  • Mr. Brenton Taylor, Exec. VP of Engineering (Age 38)
  • Ms. Alison Perry Bauerlein, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)
  • Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40)
  • Mr. Bart Sanford, Exec. VP of Operations (Age 53)

Who are Inogen's major shareholders?

Inogen's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.46%), Norges Bank (1.81%), Dimensional Fund Advisors LP (1.65%), New York State Common Retirement Fund (1.44%), Northern Trust Corp (1.38%) and Jennison Associates LLC (1.09%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

Which institutional investors are selling Inogen stock?

INGN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prudential Financial Inc., Acadian Asset Management LLC, Jane Street Group LLC, Virtu Financial LLC, Timpani Capital Management LLC, Public Employees Retirement System of Ohio and New York State Common Retirement Fund. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.

Which institutional investors are buying Inogen stock?

INGN stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Thrivent Financial for Lutherans, Jennison Associates LLC, BlackRock Inc., Polar Capital LLP, Kornitzer Capital Management Inc. KS, Northern Trust Corp and Peregrine Capital Management LLC. View Insider Buying and Selling for Inogen.

How do I buy shares of Inogen?

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inogen's stock price today?

One share of INGN stock can currently be purchased for approximately $90.12.

How big of a company is Inogen?

Inogen has a market capitalization of $1.97 billion and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.

What is Inogen's official website?

The official website for Inogen is http://www.inogen.com.

How can I contact Inogen?

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]


MarketBeat Community Rating for Inogen (NASDAQ INGN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  473
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel